Slide 1: BioShares Presentation, 24 July 2023
BIOSHARES PRESENTATION 2 4 J U L Y , 2023 S teven Lydeamore NASD A Q: I M RN ASX: IMC - C E O
Slide 2: Safe Harbor Statement
SA F E HARB O R STAT E M E NT Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “seeks,” “estimates,” “ guidance” and s i
Slide 3: Topics
T O P I C S 1. Immuron Overview 2. US Department of Defense interest in Immuron Technology 3. Immuron’s DoD partnered programs 4. Commercial path forward if Travelan® Phase 2 study is successful 5. Partnering with the US Department of Defense 3
Slide 4: Executive Summary
EX E CU T I V E SU M MARY Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases C o m p a n y O v e rv i e w Bu s i nes s Update R esu l ts & Outlook • Two
Slide 5: Addressable Market & Industry Overview
ADDRESSABLE MARKET & I N D U ST R Y O V ER V I E W Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Indu s t r y tai l w i n d s Travel picking up significantly following C O V I D l o c k d o wn s Frequent Symptom 30% - 70% of travelers experience t
Slide 6: Technology Platform
T EC HN O L O G Y P LATF O R M Bovine colostrum is the first milk of cows after calving . It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides . Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk . This en
Slide 7: US Department of Defense
U S DE P A R TM E NT O F D E F E N S E • Managed by the Department of Defense collaborating with multiple government agencies • Focuses on development of medical solutions to protect, treat, and optimize health and performance of U.S. military personnel and civilians • Focuses on innovative medical
Slide 8: US Army Medical Research & Development Command
US ARMY MEDICAL RESEARCH & DEVELOPMENT COMMAND K ey C o mm e n t a r y • US Military Infectious Diseases Research Program (MIDRP) • The mission of the MIDRP is to plan, coordinate and oversee for the US DOD r e q u i r em e n t s - d ri v en med i c a l s o l u t i o n s t h at P R E V E N T , P R E
Slide 9: US DoD R&D Collaboration Agreements
U S DO D R & D C OL L A B O RA T IO N A G R EE M E NT S Established Developing K ey C o mm e n t a r y Australian Packaging U S A P ack ag i n g ▪ Immuron partnered with AFRIMS, NMRC & WRAIR to test Travelan® against Campylobacter, ETEC, Shigella and Vibrio cholera ▪ Walter Reed Army Institute of Re
Slide 10: Travelan Drug Development Plan
TRAVELAN® DRUG DEVELOPMENT PLAN Travelan® for FDA approval as biologic to reduce the risk of traveller’s diarrhoea (TD) in travellers to endemic areas: D o D - sup p o r t e d challenge trial x x A ss i mi l ate Da t a to Support IND Submission to FDA Hold Pre - IND Meeting to D is c us s M e r i ts
Slide 11: Travelan Drug Development Plan
TRAVELAN® DRUG DEVELOPMENT PLAN Travelan® sits around Milestone B. In applying for the MTEC grant, Immuron had a high TRL rating. The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Army, Department
Slide 12: Partnering with US Department of Defense
P A R TN E R I N G W I T H U S DE P A R T M E N T O F DE F E N S E • Join funding consortiums like MTEC which the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies offer funding opportunities to members through solicitations called Requests for Prototype Proposals (
Slide 13: Steven Lydeamore, Chief Executive Officer
STEVEN LYDEAMORE C HIE F EXE C U T IVE O F FI C ER IMMURON LIMITED C O NT AC T I N FO R MA T IO N : EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 13
Slide 14: Scientific References
S C I E NT I FIC R E F E R E N C E S T r a v e l a n® (I MM - 124 E ) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers I mm u r o n
Slide 15: Partnering with US Department of Defense: Acronyms
P A R T N ER ING W I T H U S D E P AR T M E N T O F D E F E N S E LEARN YOUR ACRONYMS Abbreviations Acronyms Abbreviations Acronyms Naval Advanced Medical Development NAMD Animal Care and Use Review Office ACURO Nontraditional Defense Contractor NDC A d vanc e d T e c h n o l o g y I n t e r n at i